Install
Biotech and pharma business news, with a focus on the science, people and money that drive the industry.
- 80articles · 30d
- 1+ day agolatest article
- Aug 17, 2026earliest in window
- 94%with images
- 85avg words
- health 48
- business 33
- biotech 28
- biotechnology 23
- fda 23
- pharma 21
- drug development 19
- cancer 18
- type-newspost 17
- clinical trials 15
- oncology 13
- artificial intelligence 11
- biopharma 11
- globenewswire 11
- pharmaceuticals 11
- science 11
- stat+ 11
- tmt newswire 11
- business & health 10
- (midwest communications 9
- Health & Wellness 63
- Medical 56
- Health 28
- Science & Technology 26
- Economy, Business & Finance 21
- Finance & Business 17
- Business & Industrial 12
- Science & Nature 5
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
1+ day, 8+ hour ago (76+ words) Endpoints News Akeso details survival win for its PD-1xVEGF drug versus Keytruda Akeso and Summit Therapeutics claimed a key win over Keytruda at the start of September,…...
How past Endpoints 11 winners fared as the biotech industry rebounded
3+ day, 20+ hour ago (64+ words) Endpoints News How past Endpoints 11 winners fared as the biotech industry rebounded We’ll be unveiling this year’s Endpoints 11 in Boston on the night of Sept. 24. Join us. Think we're worth reading…...
Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label in NSCLC
3+ day, 19+ hour ago (52+ words) Endpoints News Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label in NSCLC Plus news about Tevard Biosciences, Disc Medicine, InduPro, EMD Serono and Frazier Life Sciences....
Expanding its biopharma plans, Anthropic looks for a life-sciences dealmaker
5+ day, 18+ hour ago (92+ words) Endpoints News Expanding its biopharma plans, Anthropic looks for a life-sciences dealmaker Anthropic’s newest job posting confirms the company’s biotech dealmaking ambi…...
Moonwalk raises $70M to test siRNA treatment for obesity
5+ day, 22+ hour ago (75+ words) Endpoints News Moonwalk raises $70M to test siRNA treatment for obesity Moonwalk Biosciences is heading to the clinic with an obesity program and has raised $70 million for…...
Roivant reports Phase 2 win for lung disease drug that it got from Bayer
6+ day, 36+ min ago (151+ words) #ERS26: Roivant reports Phase 2 win for lung disease drug that it got from Bayer Endpoints News We value your privacy We use third-party cookies that help us analyze how you use this website and store your preferences. However, you can opt…...
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
1+ week, 2+ day ago (91+ words) Endpoints News CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of…...
FDA conveys tougher clamp down of foreign trial data coinciding with China’s rise
1+ week, 4+ day ago (93+ words) Endpoints News FDA conveys tougher clamp down of foreign trial data coinciding with China’s rise Top FDA leaders are doubling down on clinical trial oversight mea…...
Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors
1+ week, 5+ day ago (88+ words) Endpoints News Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors At least 50 different venture investors have benefited from Eli Lilly’s dealmak…...
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward"
1+ week, 5+ day ago (80+ words) Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' Endpoints News Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' Alumis’ lead drug program suffered…...